ccxi-10q_20200930.htm
false 2020 Q3 0001340652 --12-31 2031-02 2020-06 P2Y6M7D P1Y10M20D P2Y P10Y 0 P6Y9M P6Y8M1D P5Y5M26D 0001340652 2020-01-01 2020-09-30 xbrli:shares 0001340652 2020-10-31 iso4217:USD 0001340652 2020-09-30 0001340652 2019-12-31 iso4217:USD xbrli:shares 0001340652 2020-07-01 2020-09-30 0001340652 2019-07-01 2019-09-30 0001340652 2019-01-01 2019-09-30 0001340652 us-gaap:CommonStockMember 2020-06-30 0001340652 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001340652 ccxi:EmployeeNoteReceivableMember 2020-06-30 0001340652 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0001340652 us-gaap:RetainedEarningsMember 2020-06-30 0001340652 2020-06-30 0001340652 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001340652 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001340652 ccxi:EmployeeNoteReceivableMember 2020-07-01 2020-09-30 0001340652 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-01 2020-09-30 0001340652 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001340652 us-gaap:CommonStockMember 2020-09-30 0001340652 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001340652 ccxi:EmployeeNoteReceivableMember 2020-09-30 0001340652 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 0001340652 us-gaap:RetainedEarningsMember 2020-09-30 0001340652 us-gaap:CommonStockMember 2019-12-31 0001340652 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001340652 ccxi:EmployeeNoteReceivableMember 2019-12-31 0001340652 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001340652 us-gaap:RetainedEarningsMember 2019-12-31 0001340652 us-gaap:CommonStockMember 2020-01-01 2020-09-30 0001340652 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-09-30 0001340652 ccxi:EmployeeNoteReceivableMember 2020-01-01 2020-09-30 0001340652 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-09-30 0001340652 us-gaap:RetainedEarningsMember 2020-01-01 2020-09-30 0001340652 us-gaap:CommonStockMember 2019-06-30 0001340652 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001340652 ccxi:EmployeeNoteReceivableMember 2019-06-30 0001340652 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0001340652 us-gaap:RetainedEarningsMember 2019-06-30 0001340652 2019-06-30 0001340652 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0001340652 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0001340652 ccxi:EmployeeNoteReceivableMember 2019-07-01 2019-09-30 0001340652 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-01 2019-09-30 0001340652 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0001340652 us-gaap:CommonStockMember 2019-09-30 0001340652 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001340652 ccxi:EmployeeNoteReceivableMember 2019-09-30 0001340652 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0001340652 us-gaap:RetainedEarningsMember 2019-09-30 0001340652 2019-09-30 0001340652 us-gaap:CommonStockMember 2018-12-31 0001340652 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001340652 ccxi:EmployeeNoteReceivableMember 2018-12-31 0001340652 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001340652 us-gaap:RetainedEarningsMember 2018-12-31 0001340652 2018-12-31 0001340652 us-gaap:CommonStockMember 2019-01-01 2019-09-30 0001340652 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-09-30 0001340652 ccxi:EmployeeNoteReceivableMember 2019-01-01 2019-09-30 0001340652 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-09-30 0001340652 us-gaap:RetainedEarningsMember 2019-01-01 2019-09-30 0001340652 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 2019-09-30 ccxi:Segment 0001340652 ccxi:USFoodAndDrugAdministrationMember 2020-09-30 0001340652 ccxi:USFoodAndDrugAdministrationMember 2019-12-31 0001340652 ccxi:ViforInternationalLtdMember 2020-09-30 0001340652 ccxi:ViforInternationalLtdMember 2019-12-31 0001340652 ccxi:StockOptionsAndEmployeeStockPurchasePlanMember 2020-07-01 2020-09-30 0001340652 ccxi:StockOptionsAndEmployeeStockPurchasePlanMember 2019-07-01 2019-09-30 0001340652 us-gaap:RestrictedStockUnitsRSUMember 2020-07-01 2020-09-30 0001340652 us-gaap:RestrictedStockUnitsRSUMember 2019-07-01 2019-09-30 0001340652 us-gaap:RestrictedStockMember 2020-07-01 2020-09-30 0001340652 us-gaap:RestrictedStockMember 2019-07-01 2019-09-30 0001340652 us-gaap:WarrantMember 2020-07-01 2020-09-30 0001340652 us-gaap:WarrantMember 2019-07-01 2019-09-30 0001340652 ccxi:StockOptionsAndEmployeeStockPurchasePlanMember 2020-01-01 2020-09-30 0001340652 ccxi:StockOptionsAndEmployeeStockPurchasePlanMember 2019-01-01 2019-09-30 0001340652 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-09-30 0001340652 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-09-30 0001340652 us-gaap:RestrictedStockMember 2020-01-01 2020-09-30 0001340652 us-gaap:RestrictedStockMember 2019-01-01 2019-09-30 0001340652 us-gaap:WarrantMember 2020-01-01 2020-09-30 0001340652 us-gaap:WarrantMember 2019-01-01 2019-09-30 0001340652 us-gaap:OtherAssetsMember 2020-09-30 0001340652 us-gaap:OtherAssetsMember 2019-12-31 0001340652 us-gaap:MoneyMarketFundsMember 2020-09-30 0001340652 us-gaap:USTreasurySecuritiesMember 2020-09-30 0001340652 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-09-30 0001340652 us-gaap:CommercialPaperMember 2020-09-30 0001340652 us-gaap:AssetBackedSecuritiesMember 2020-09-30 0001340652 us-gaap:CorporateDebtSecuritiesMember 2020-09-30 0001340652 us-gaap:MoneyMarketFundsMember 2019-12-31 0001340652 us-gaap:USTreasurySecuritiesMember 2019-12-31 0001340652 us-gaap:CommercialPaperMember 2019-12-31 0001340652 us-gaap:AssetBackedSecuritiesMember 2019-12-31 0001340652 us-gaap:CorporateDebtSecuritiesMember 2019-12-31 ccxi:Investment 0001340652 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001340652 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001340652 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001340652 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001340652 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001340652 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001340652 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001340652 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001340652 us-gaap:AgencySecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001340652 us-gaap:AgencySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001340652 us-gaap:AgencySecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001340652 us-gaap:AgencySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001340652 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001340652 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001340652 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001340652 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001340652 us-gaap:AssetBackedSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001340652 us-gaap:AssetBackedSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001340652 us-gaap:AssetBackedSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001340652 us-gaap:AssetBackedSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001340652 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001340652 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001340652 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001340652 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001340652 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001340652 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001340652 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001340652 us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001340652 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001340652 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001340652 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001340652 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001340652 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001340652 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001340652 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001340652 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001340652 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001340652 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001340652 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001340652 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001340652 us-gaap:AssetBackedSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001340652 us-gaap:AssetBackedSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001340652 us-gaap:AssetBackedSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001340652 us-gaap:AssetBackedSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001340652 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001340652 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001340652 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001340652 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001340652 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001340652 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001340652 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001340652 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001340652 ccxi:TermLoanMember 2020-09-30 0001340652 ccxi:TermLoanMember 2019-12-31 0001340652 ccxi:TermLoanMember 2017-12-28 xbrli:pure 0001340652 2017-12-28 2017-12-28 0001340652 ccxi:TermLoanMember 2020-01-01 2020-09-30 0001340652 ccxi:TermLoanMember exch:WSAG 2020-01-01 2020-09-30 0001340652 ccxi:TermLoanRestatedMember 2020-01-08 ccxi:Tranche 0001340652 ccxi:TrancheOneMember ccxi:FifteenDecemberTwoThousandTwentyMember 2020-01-08 0001340652 ccxi:TrancheOneMember ccxi:AvacopanNewDrugApplicationMember ccxi:FifteenDecemberTwoThousandTwentyMember 2020-01-08 0001340652 ccxi:TrancheTwoMember ccxi:AvacopanNewDrugApplicationMember ccxi:FifteenDecemberTwoThousandTwentyOneMember 2020-01-08 0001340652 ccxi:TrancheThreeMember ccxi:FifteenDecemberTwoThousandTwentyTwoMember 2020-01-08 0001340652 ccxi:TrancheOneMember 2020-01-07 2020-01-08 0001340652 ccxi:TermLoanRestatedMember ccxi:TrancheOneMember 2020-03-30 2020-03-31 0001340652 ccxi:TermLoanRestatedMember exch:WSAG ccxi:TrancheOneMember 2020-01-01 2020-09-30 0001340652 ccxi:TermLoanRestatedMember ccxi:TrancheOneMember 2020-01-01 2020-09-30 0001340652 ccxi:TermLoanRestatedMember ccxi:TrancheOneMember 2020-09-30 0001340652 ccxi:TermLoanMember 2020-01-07 2020-01-08 0001340652 ccxi:TermLoanMember srt:MinimumMember 2020-01-07 2020-01-08 0001340652 ccxi:TermLoanRestatedMember srt:MinimumMember 2020-01-07 2020-01-08 0001340652 ccxi:TermLoanRestatedMember 2020-01-01 2020-09-30 0001340652 ccxi:TermLoanMember ccxi:HerculesCapitalIncMember srt:MaximumMember 2020-01-07 2020-01-08 0001340652 ccxi:HerculesCapitalIncMember 2020-01-08 0001340652 ccxi:ThirdAmendmentLeaseMember 2020-01-01 2020-09-30 utr:sqft 0001340652 ccxi:SanCarlosCaliforniaMember 2020-09-30 0001340652 us-gaap:LetterOfCreditMember 2020-09-30 0001340652 ccxi:SanCarlosCaliforniaMember 2020-01-01 2020-09-30 0001340652 ccxi:AccruedAndOtherLiabilitiesCurrentMember 2020-09-30 0001340652 ccxi:AccruedAndOtherLiabilitiesCurrentMember 2019-12-31 0001340652 ccxi:ViforInternationalLtdMember 2020-01-01 2020-09-30 0001340652 ccxi:AvacopanAgreementMember 2016-05-01 2016-05-31 0001340652 ccxi:AvacopanAmendmentMember 2017-02-01 2017-02-28 0001340652 ccxi:AvacopanLetterAgreementMember 2018-06-01 2018-06-30 0001340652 srt:MaximumMember ccxi:AvacopanAgreementMember 2020-01-01 2020-09-30 0001340652 ccxi:AvacopanAgreementMember 2017-12-01 2017-12-31 0001340652 ccxi:AvacopanAgreementMember 2020-09-30 0001340652 2016-05-01 2016-05-31 0001340652 2016-05-09 0001340652 ccxi:AvacopanLetterAgreementMember 2017-12-28 2017-12-28 0001340652 ccxi:AvacopanAgreementMember 2020-07-01 2020-09-30 0001340652 ccxi:AvacopanAgreementMember 2020-01-01 2020-09-30 0001340652 ccxi:AvacopanAgreementMember 2019-07-01 2019-09-30 0001340652 ccxi:AvacopanAgreementMember 2019-01-01 2019-09-30 0001340652 ccxi:Ccx140AgreementMember 2017-01-01 2017-12-31 0001340652 ccxi:Ccx140AgreementMember 2018-06-01 2018-06-30 0001340652 ccxi:Ccx140AgreementMember 2020-09-30 0001340652 ccxi:Ccx140AgreementMember 2020-01-01 2020-09-30 0001340652 ccxi:Ccx140AgreementMember ccxi:ViforInternationalLtdMember 2020-01-01 2020-09-30 0001340652 ccxi:Ccx140AgreementMember 2020-07-01 2020-09-30 0001340652 ccxi:Ccx140AgreementMember 2019-07-01 2019-09-30 0001340652 ccxi:Ccx140AgreementMember 2019-01-01 2019-09-30 0001340652 ccxi:AccountsReceivableNetMember 2020-09-30 0001340652 ccxi:AccountsReceivableNetMember 2019-12-31 0001340652 ccxi:DeferredRevenueMember 2020-09-30 0001340652 ccxi:DeferredRevenueMember 2019-12-31 0001340652 us-gaap:GrantMember 2020-07-01 2020-09-30 0001340652 us-gaap:GrantMember 2020-01-01 2020-09-30 0001340652 us-gaap:GrantMember 2020-09-30 0001340652 ccxi:USFoodAndDrugsAdministrationMember 2019-09-01 2019-09-30 0001340652 ccxi:RestrictedStockUnitsAndRestrictedStockAwardsMember 2019-12-31 0001340652 ccxi:RestrictedStockUnitsAndRestrictedStockAwardsMember 2020-01-01 2020-09-30 0001340652 ccxi:RestrictedStockUnitsAndRestrictedStockAwardsMember 2020-09-30 0001340652 us-gaap:EmployeeStockOptionMember 2020-07-01 2020-09-30 0001340652 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0001340652 us-gaap:EmployeeStockOptionMember 2019-07-01 2019-09-30 0001340652 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-09-30 0001340652 us-gaap:EmployeeStockOptionMember 2020-09-30 0001340652 us-gaap:EmployeeStockMember 2020-09-30 0001340652 us-gaap:EmployeeStockMember 2020-07-01 2020-09-30 0001340652 ccxi:FEPOMember 2020-04-01 2020-06-30 0001340652 ccxi:FEPOMember 2020-06-30

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

Form 10-Q

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2020

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from              to             

 

Commission File Number: 001-35420

ChemoCentryx, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

Delaware

94-3254365

(State or Other Jurisdiction of

Incorporation or Organization)

(I.R.S. Employer

Identification No.)

 

 

850 Maude Avenue

Mountain View, California

94043

(Address of Principal Executive Offices)

(Zip Code)

 

(650) 210-2900

(Registrant’s Telephone Number, Including Area Code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.001 per share

CCXI

The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒  No   

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    ☒  Yes      No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

Accelerated filer

Non-accelerated filer

 

Smaller reporting company

 

 

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13 (a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes      No  

The number of outstanding shares of the registrant’s common stock, par value $0.001 per share, as of October 31, 2020 was 69,208,414.

 

 

 


 

CHEMOCENTRYX, INC.

 

QUARTERLY REPORT ON FORM 10-Q

For the quarterly period ended September 30, 2020

Table of Contents

 

 

 

 

PART I. FINANCIAL INFORMATION

Page

 

 

 

Item 1.

Financial Statements (Unaudited)

3

 

 

 

 

Condensed Consolidated Balance Sheets – September 30, 2020 and December 31, 2019

3

 

 

 

 

Condensed Consolidated Statements of Operations – Three and Nine Months Ended September 30, 2020 and 2019

4

 

 

 

 

Condensed Consolidated Statements of Comprehensive Loss – Three and Nine Months Ended September 30, 2020 and 2019

5

 

 

 

 

Condensed Consolidated Statements of Stockholders’ Equity – Three and Nine Months Ended September 30, 2020 and 2019

6

 

 

 

 

Condensed Consolidated Statements of Cash Flows – Nine Months Ended September 30, 2020 and 2019

8

 

 

 

 

Notes to Condensed Consolidated Financial Statements

9

 

 

 

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

21

 

 

 

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

28

 

 

 

Item 4.

Controls and Procedures

29

 

 

PART II. OTHER INFORMATION

 

 

 

 

Item 1.

Legal Proceedings

30

 

 

 

Item 1A.

Risk Factors

30

 

 

 

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

31

 

 

 

Item 3.

Defaults Upon Senior Securities

31

 

 

 

Item 4.

Mine Safety Disclosures

31

 

 

 

Item 5.

Other Information

31

 

 

 

Item 6.

Exhibits

31

 

 

EXHIBIT INDEX

32

 

 

SIGNATURES

33

 

2


 

PART I. FINANCIAL INFORMATION

Item 1.

Financial Statements

CHEMOCENTRYX, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except share and par value data)

(unaudited)

 

 

 

September 30,

 

 

December 31,

 

 

 

2020

 

 

2019

 

Assets

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

56,177

 

 

$

39,179

 

Short-term investments

 

 

415,207

 

 

 

133,607

 

Accounts receivable, other

 

 

44

 

 

 

176

 

Accounts receivable from related party

 

 

58

 

 

 

 

Prepaid expenses and other current assets

 

 

2,956

 

 

 

1,400

 

Total current assets

 

 

474,442

 

 

 

174,362

 

Property and equipment, net

 

 

15,063

 

 

 

2,154

 

Long-term investments

 

 

14,456

 

 

 

29,454

 

Operating lease right-of-use assets

 

 

27,667

 

 

 

1,704

 

Other assets

 

 

1,414

 

 

 

1,409

 

Total assets

 

$

533,042

 

 

$

209,083

 

Liabilities and Stockholders’ Equity

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

8,868

 

 

$

1,532

 

Accrued and other current liabilities

 

 

18,938

 

 

 

19,806

 

Long-term debt, current

 

 

3,066

 

 

 

 

Other current liabilities to related party

 

 

6,173

 

 

 

 

Deferred revenue from related party

 

 

9,817

 

 

 

37,742

 

Total current liabilities

 

 

46,862

 

 

 

59,080

 

Long-term debt, net

 

 

21,260

 

 

 

19,786

 

Non-current deferred revenue from related party

 

 

24,814

 

 

 

63,095

 

Non-current lease liabilities

 

 

34,436

 

 

 

566

 

Other non-current liabilities

 

 

851

 

 

 

556

 

Total liabilities

 

 

128,223

 

 

 

143,083

 

Commitments (Note 7)

 

 

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

 

 

Preferred stock, $0.001 par value, 10,000,000 shares authorized;

   no shares issued and outstanding

 

 

 

 

 

 

Common stock, $0.001 par value, 200,000,000 shares authorized;

  69,108,573 and 60,234,784 shares issued and outstanding at

  September 30, 2020 and December 31, 2019, respectively

 

 

69

 

 

 

60

 

Additional paid-in capital

 

 

859,960

 

 

 

495,624

 

Note receivable

 

 

(16

)

 

 

(16

)

Accumulated other comprehensive income

 

 

272

 

 

 

318

 

Accumulated deficit

 

 

(455,466

)

 

 

(429,986

)

Total stockholders’ equity

 

 

404,819

 

 

 

66,000

 

Total liabilities and stockholders’ equity

 

$

533,042

 

 

$

209,083

 

 

See accompanying notes.

3


 

CHEMOCENTRYX, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share data)

(unaudited)

 

 

 

Three Months Ended

September 30,

 

 

Nine Months Ended

September 30,

 

 

 

2020

 

 

2019

 

 

2020

 

 

2019

 

Revenue:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Collaboration and license revenue from related party

 

$

5,027

 

 

$

10,581

 

 

$

60,165

 

 

$

26,081

 

Grant revenue

 

 

58

 

 

 

 

 

 

368

 

 

 

 

Total revenue

 

 

5,085

 

 

 

10,581

 

 

 

60,533

 

 

 

26,081

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

18,582

 

 

 

18,096

 

 

 

56,655

 

 

 

51,074

 

General and administrative

 

 

10,362

 

 

 

6,116

 

 

 

29,474

 

 

 

17,187

 

Total operating expenses

 

 

28,944

 

 

 

24,212

 

 

 

86,129

 

 

 

68,261

 

Loss from operations

 

 

(23,859

)

 

 

(13,631

)

 

 

(25,596

)

 

 

(42,180

)

Other income (expense):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest income

 

 

499

 

 

 

1,311

 

 

 

2,059

 

 

 

3,850

 

Interest expense

 

 

(700

)

 

 

(542

)

 

 

(1,943

)

 

 

(1,631

)

Total other income (expense), net

 

 

(201

)

 

 

769

 

 

 

116

 

 

 

2,219

 

Net loss

 

$

(24,060

)

 

$

(12,862

)

 

$

(25,480

)

 

$

(39,961

)

Basic and diluted net loss per common share

 

$

(0.35

)

 

$

(0.22

)

 

$

(0.40

)

 

$

(0.71

)

Shares used to compute basic and diluted net loss per

    common share

 

 

68,922

 

 

 

58,205

 

 

 

64,500

 

 

 

56,219

 

 

See accompanying notes.

4


 

CHEMOCENTRYX, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

 

(in thousands)

(unaudited)

 

 

 

Three Months Ended

September 30,

 

 

Nine Months Ended

September 30,

 

 

 

2020

 

 

2019

 

 

2020

 

 

2019

 

Net loss

 

$

(24,060

)

 

$

(12,862

)

 

$

(25,480

)

 

$

(39,961

)

Unrealized gain (loss) on available-for-sale securities

 

 

(216

)

 

 

56

 

 

 

(46

)

 

 

607

 

Comprehensive loss

 

$

(24,276

)

 

$

(12,806

)

 

$

(25,526

)

 

$

(39,354

)

 

See accompanying notes.

5


 

CHEMOCENTRYX, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

 

(in thousands, except share data)

(unaudited)

 

 

 

Common Stock

 

 

Additional

Paid-In

 

 

Note

 

 

Accumulated

Other

Comprehensive

 

 

Accumulated

 

 

Total

Stockholders'

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Receivable

 

 

Income

 

 

Deficit

 

 

Equity

 

Balance as of June 30, 2020

 

 

68,803,400

 

 

$

69

 

 

$

852,006

 

 

$

(16

)

 

$

488

 

 

$

(431,406

)

 

$

421,141

 

Net loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(24,060

)

 

 

(24,060

)

Unrealized loss on investments

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(216

)

 

 

-

 

 

 

(216

)

Issuance of common stock under

    equity incentive plans

 

 

305,173

 

 

 

-

 

 

 

2,005

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

2,005

 

Employee stock-based compensation

 

 

-

 

 

 

-

 

 

 

5,721

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

5,721

 

Compensation expense related to

    options granted to consultants

 

 

-

 

 

 

-

 

 

 

228

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

228

 

Balance as of September 30, 2020

 

 

69,108,573

 

 

$

69

 

 

$

859,960

 

 

$

(16

)

 

$

272

 

 

$

(455,466

)

 

$

404,819

 

 

 

 

Common Stock

 

 

Additional

Paid-In

 

 

Note

 

 

Accumulated

Other

Comprehensive

 

 

Accumulated

 

 

Total

Stockholders'

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Receivable

 

 

Income

 

 

Deficit

 

 

Equity

 

Balance as of December 31, 2019

 

 

60,234,784

 

 

$

60

 

 

$

495,624

 

 

$

(16

)

 

$

318

 

 

$

(429,986

)

 

$

66,000

 

Net loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(25,480

)

 

 

(25,480

)

Unrealized loss on investments

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(46

)

 

 

-

 

 

 

(46

)

Issuance of common stock upon

    follow-on offering, net of

    issuance costs

 

 

5,980,000

 

 

 

6

 

 

 

325,648

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

325,654

 

Issuance of common stock under

    equity incentive plans

 

 

2,986,248

 

 

 

3

 

 

 

26,495

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

26,498

 

Repurchased shares upon vesting of

    restricted stock units for tax

    withholdings

 

 

(92,459

)

 

 

-

 

 

 

(3,709

)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(3,709

)

Employee stock-based compensation

 

 

-

 

 

 

-

 

 

 

15,171

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

15,171

 

Compensation expense related to

    options granted to consultants

 

 

-

 

 

 

-

 

 

 

731

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

731

 

Balance as of September 30, 2020

 

 

69,108,573

 

 

$

69

 

 

$

859,960

 

 

$

(16

)

 

$

272

 

 

$

(455,466

)

 

$

404,819

 

 

See accompanying notes.

 


6


 

CHEMOCENTRYX, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

 

(in thousands, except share data)

(unaudited)

 

 

 

Common Stock

 

 

Additional

Paid-In

 

 

Note

 

 

Accumulated

Other

Comprehensive

 

 

Accumulated

 

 

Total

Stockholders'

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Receivable

 

 

Income (Loss)

 

 

Deficit

 

 

Equity

 

Balance as of June 30, 2019

 

 

58,209,745

 

 

$

58

 

 

$

472,661

 

 

$

(16

)

 

$

353

 

 

$

(401,596

)

 

$

71,460

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(12,862

)

 

 

(12,862

)

Unrealized gain on investments

 

 

 

 

 

 

 

 

 

 

 

 

 

 

56

 

 

 

 

 

 

56

 

Issuance of common stock under equity

   incentive and employee stock purchase plans

 

 

43,395

 

 

 

 

 

 

269

 

 

 

 

 

 

 

 

 

 

 

 

269

 

Employee stock-based compensation

 

 

 

 

 

 

 

 

2,856

 

 

 

 

 

 

 

 

 

 

 

 

2,856

 

Compensation expense related to options

   granted to consultants

 

 

 

 

 

 

 

 

83

 

 

 

 

 

 

 

 

 

 

 

 

83

 

Balance as of September 30, 2019

 

 

58,253,140

 

 

$

58

 

 

$

475,869

 

 

$

(16

)

 

$

409

 

 

$

(414,458

)

 

$

61,862

 

 

 

 

Common Stock

 

 

Additional

Paid-In

 

 

Note

 

 

Accumulated

Other

Comprehensive

 

 

Accumulated

 

 

Total

Stockholders'

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Receivable

 

 

Income (Loss)

 

 

Deficit

 

 

Equity

 

Balance as of December 31, 2018

 

 

50,652,238

 

 

$

51

 

 

$

389,398

 

 

$

(16

)

 

$

(198

)

 

$

(374,497

)

 

$

14,738

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(39,961

)

 

 

(39,961

)

Unrealized gain on investments

 

 

 

 

 

 

 

 

 

 

 

 

 

 

607

 

 

 

 

 

 

607

 

Issuance of common stock under Equity

    Distribution Agreement, net of issuance

    costs

 

 

6,491,196

 

 

 

6

 

 

 

73,270

 

 

 

 

 

 

 

 

 

 

 

 

73,276

 

Issuance of common stock under equity

   incentive and employee stock purchase plans

 

 

1,217,325

 

 

 

1

 

 

 

5,836

 

 

 

 

 

 

 

 

 

 

 

 

5,837

 

Repurchased shares upon vesting of restricted

    stock units for tax withholdings

 

 

(107,619

)

 

 

 

 

 

(1,174

)

 

 

 

 

 

 

 

 

 

 

 

(1,174

)

Employee stock-based compensation

 

 

 

 

 

 

 

 

8,359

 

 

 

 

 

 

 

 

 

 

 

 

8,359

 

Compensation expense related to options

   granted to consultants

 

 

 

 

 

 

 

 

180

 

 

 

 

 

 

 

 

 

 

 

 

180

 

Balance as of September 30, 2019

 

 

58,253,140

 

 

$

58

 

 

$

475,869

 

 

$